Previous 10 | Next 10 |
Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MAB TM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories. COF has completed the pati...
Sorrento Therapeutics (NASDAQ:SRNE +5.6%) said on Tuesday it had received clearance from the FDA for its application to begin trial for a Phase 2 study of Abivertinib to be conducted in participants with metastatic castrate resistant prostate cancer ((mCRPC)) at multiple center...
FDA granted IND clearance for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States. Abivertinib is a novel small molecule tyrosine kinase inh...
PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nas...
SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM p...
SP-102 (SEMDEXA TM ) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its primary endpoint with a hig...
A166 is a third-generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena Biopharma’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock™ conjugation chemistry. A166 has demonstrated promising antitumor a...
A rising stock price is the cure for any investor's glum mood. Sorrento Therapeutics (NASDAQ: SRNE) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company's coronavirus drug candidate. That morning, Sorre...
Hot Penny Stocks For Your Watchlist as the Stock Market Falls Again While investing in penny stocks is never easy, doing so during a market crash is even more difficult. The key to success when it comes to buying penny stocks is to find the right stocks at the right time. To do this...
The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but only 5 minor adverse events requiring no treatment have been reported in the entire study to date, similar to the safety profile observed in Sorrento’s CO...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...